Phase 4 N=81 Artificial Tears, Tear Lipids and Tear Film Dynamics
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=105 Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Dry Eye Syndrome
Primary: Global Ocular Staining (With Oxford Scale - Ranges : 0-15) — -2.5; -2.7 score on a scale
Phase 2 N=51 A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
Dry Eye Syndromes
Primary: Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale. — -0.81; -0.75; -0.82 units on a scale
Phase 4 N=20 Effects of Dry Eye Treatments on the Ocular Surface
Keratoconjunctivitis Sicca · Dry Eye Syndrome
Primary: Changes in Corneal Fluorescein Staining — 22.18; -3.35 units on a scale — p=<0.05
N/A N=26 SYSTANE® Family - Meibomian Deficiency
Dry Eye Syndrome
Primary: Number of Meibomian Glands Yielding Liquid Secretion (MGLYS) — 3.5; 4.2; 7.0; 3.9 functioning glands
Phase 3 N=93 Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome
Dry Eye Syndromes
Primary: Global Ocular Staining (With Oxford Scale - Ranges :0-15) — -1.8; -2 scores on a scale
N/A N=10 Controlled Adverse Environment: A Pilot Study to Evaluate Tear Film Stability and Tear Evaporation
Environmental Exposure
Primary: Tear Evaporation Rate — 39.0; 44.8; 30.6; 26.7 Watt/meter^2
N/A N=62 Efficacy, Safety of T2769 in Dry Eye Disease
Dry Eye Syndrome
Primary: Ocular Symptomatology — -55.9 units on a scale
N/A N=20 Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms
Dry Eye Syndrome
Primary: Change in Schirmer's Scores — -.30; -1.06 score on a scale
N/A N=15 Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation
Aqueous Deficient Dry Eye · Meibomium Gland Dysfunction
Primary: Visual Quality — 0.3; 0.32; 0.19; 0.3 microns
N/A N=57 Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
Dry Eye · Dry Eye Syndromes
Primary: Eye Dryness Score — 48 Score on Scale — p=0.0001
Phase 2 N=84 Dry Eye Disease Study With Brimonidine
Dry Eye
Primary: Tolerance of Test Substance Visual Analogue Scale (VAS) Score — 82.1; 87.0; 95.0; 91.1 score on a scale
Phase 2 N=201 Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining (tCFS) at Day 60 — -2.04; -1.65; -2.15; -1.54 tCFS score on a scale of 0 - 20
N/A N=54 SYSTANE® BALANCE Symptoms (OSDI) & Inflammatory Biomarkers
Dry Eye Syndrome
Primary: Ocular Comfort Measured as Mean Change From Baseline in OSDI Score by Visit — -7.85; -12.58; -10.23; -16.74 units on a scale
N/A N=26 Mechanisms of Light-based Therapies for Dry Eye Disease
Dry Eye Syndromes · Meibomian Gland Dysfunction
Primary: Change From Baseline in Non-invasive Tear Break Up Time to the Final Follow-up 3 Months After Final Treatment Session — -2.61; -0.85 seconds
Phase 3 N=42 Acupuncture for Dry Eye Syndrome
Dry Eye Syndromes
Primary: Ocular Surface Disease Index : OSDI — -17.61; -17.20 Scores on the OSDI score
Phase 2 N=69 Safety and Efficacy of TOP1630 for Dry Eye Syndrome
Dry Eye Syndrome
Primary: Visual Acuity — 0.05; -0.09; 0.017; 0.075 logMAR
Phase 2 N=356 Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome
Dry Eye Syndrome
Primary: Mean Corneal Staining Score — 4.0; 3.9; 3.9; 4.4 score on a scale
Phase 3 N=535 Dry Eye Assessment and Management Study
Dry Eye
Primary: Mean of Change From Baseline in Ocular Surface Disease Index (OSDI) Score at 6 and 12 Months — -13.9; -12.5 units on a scale — p=0.40
N/A N=20 Tear Film Stability After Instillation of Over-the-Counter (OTC) Artificial Drops
Dry Eye Disease
Primary: Aqueous Tear Evaporation Rate Before and After Use of OTC Artificial Tears — 0.047; 0.049; 0.031; 0.032 (µl/cm2/min)
N/A N=200 Impairment of Reading Ability in Dry Eye Patients
Dry Eye Syndromes
Primary: Sustained Silent Reading Speed — 248.4; 270.3 words/minute
N/A N=235 TearCare System to Treat Dry Eye Disease
Dry Eye · Meibomian Gland Dysfunction
Primary: Change in Tear Break-Up Time (TBUT) From Baseline — 3.02; 2.58 Seconds
Phase 3 N=400 Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
Dry Eye Disease (DED)
Primary: Change From Baseline in Total Staining Score at Day 90 in the Study Eye — -4.5; -3.4 score on a scale — p=0.0475
N/A N=200 Clinical Evaluation of Systane® Gel Drops in Dry Eye Subjects
Dry Eye
Primary: Change From Baseline in Corneal Staining at All Study Time Points — -2.7; -4.0 units on a scale
N/A N=781 Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Ocular Surface Disease Index (OSDI) Total Score at Baseline — 40.3 Scores on a Scale
N/A N=109 Evaluation of SYSTANE Ultra Lubricant Eye Drops
Dry Eye
Primary: Tear Break-up Time — 4.2; 4.5; 4.7; 4.2 seconds
N/A N=139 Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye
Chalazion · Dry Eye Syndromes
Primary: Meibomian Gland Assessment (Total Meibomian Gland Secretion Score) — 6.3; 5.6; 14.3; 6.1 Scores on a scale
N/A N=91 Evaluation of SYSTANE® BALANCE in Dry Eye Subjects With Lipid Deficiency
Dry Eye Syndrome · Lipid Deficiency
Primary: Mean Bulbar Conjunctival Staining — 0.743; 0.442; 0.531; 0.443 percentage of staining
N/A N=314 TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Diagnostic Test Data for Disease Using Tear Osmolarity Threshold > 308 mOsm/L — 177; 14; 47; 61 participants
Phase 2 N=38 Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease
Dry Eye Disease
Primary: Mean Change From Baseline in Average Lissamine Green Staining in the Study Eye — -0.65 score on a scale